Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Preferred Stock Additional Paid-in Capital [Member] Series B Convertible Preferred Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock, Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Preferred Stock Additional Paid-in Capital [Member] Series B Convertible Preferred Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Common Stock [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Common Stock, Additional Paid-in Capital [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Retained Earnings [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock, Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019													671		9,130,984
Balance at Dec. 31, 2019													$ 1	$ 670,999	$ 1,643,565	$ 104,912,480	$ (94,071,040)	$ 13,156,005
Compensation cost for stock options granted													0	0	0	687,752	0	687,752
Net loss													$ 0	0	$ 0	0	(2,947,420)	(2,947,420)
Balance (in shares) at Mar. 31, 2020													671		9,130,984
Balance at Mar. 31, 2020													$ 1	670,999	$ 1,643,565	105,600,232	(97,018,460)	10,896,337
Balance (in shares) at Dec. 31, 2019													671		9,130,984
Balance at Dec. 31, 2019													$ 1	670,999	$ 1,643,565	104,912,480	(94,071,040)	13,156,005
Net loss																		(6,853,562)
Balance (in shares) at Jun. 30, 2020													626		9,303,878
Balance at Jun. 30, 2020													$ 1	625,999	$ 1,674,686	106,998,222	(100,924,602)	8,374,306
Balance (in shares) at Mar. 31, 2020													671		9,130,984
Balance at Mar. 31, 2020													$ 1	670,999	$ 1,643,565	105,600,232	(97,018,460)	10,896,337
Compensation cost for stock options granted													0	0	0	1,036,484	0	1,036,484
Net loss													$ 0	0	$ 0	0	(3,906,142)	(3,906,142)
Issuance of common stock, net of issuance costs of $178,544 (in shares)													0		160,108
Issuance of common stock, net of issuance costs of $178,544													$ 0	0	$ 28,820	318,807		347,627
Conversion of Series B convertible preferred stock to common stock (in shares)							(45)		12,786			(45)
Conversion of Series B convertible preferred stock to common stock							$ 0	$ (45,000)	$ 2,301	$ 42,699	$ 0	$ 0
Balance (in shares) at Jun. 30, 2020													626		9,303,878
Balance at Jun. 30, 2020													$ 1	625,999	$ 1,674,686	106,998,222	(100,924,602)	8,374,306
Balance (in shares) at Dec. 31, 2020													621		47,548,835
Balance at Dec. 31, 2020	$ 0	$ 0	$ 0	$ 9,731,714	$ 3,271,361	$ 13,003,075							$ 1	620,999	$ 8,558,778	129,887,146	(111,898,992)	27,167,932
Compensation cost for stock options granted													0	0	0	639,751	0	639,751
Net loss													$ 0	0	$ 0	0	(3,538,069)	(3,538,069)
Conversion of Series B convertible preferred stock to common stock (in shares)							(1)		285
Conversion of Series B convertible preferred stock to common stock							$ 0	(1,000)	$ 51	949	0	$ 0
Issuance of common stock and warrants, net of issuance costs of $5,493,310 (in shares)													0		41,211,100
Issuance of common stock and warrants, net of issuance costs of $5,493,310													$ 0	0	$ 7,417,998	62,250,410	0	69,668,408
Issuance of common stock upon warrant exercise (in shares)													0		32,064,148
Issuance of common stock upon warrant exercise													$ 0	0	$ 5,771,547	26,988,755	0	32,760,302
Balance (in shares) at Mar. 31, 2021													620		120,824,368
Balance at Mar. 31, 2021													$ 1	619,999	$ 21,748,374	229,498,725	(112,165,700)	139,701,399
Balance (in shares) at Dec. 31, 2020													621		47,548,835
Balance at Dec. 31, 2020	$ 0	$ 0	$ 0	$ 9,731,714	$ 3,271,361	$ 13,003,075							$ 1	620,999	$ 8,558,778	129,887,146	(111,898,992)	27,167,932
Net loss																		$ (10,577,317)
Conversion of Series B convertible preferred stock to common stock (in shares)												(34)
Issuance of common stock upon warrant exercise (in shares)																		37,155,000
Balance (in shares) at Jun. 30, 2021													587		125,925,096
Balance at Jun. 30, 2021													$ 1	586,999	$ 22,666,505	240,023,345	(119,204,948)	$ 144,071,902
Balance (in shares) at Mar. 31, 2021													620		120,824,368
Balance at Mar. 31, 2021													$ 1	619,999	$ 21,748,374	229,498,725	(112,165,700)	139,701,399
Compensation cost for stock options granted													0	0	0	1,214,110	0	1,214,110
Net loss													$ 0	0	$ 0	0	(7,039,248)	$ (7,039,248)
Conversion of Series B convertible preferred stock to common stock (in shares)							(33)		9,377			(33)
Conversion of Series B convertible preferred stock to common stock							$ 0	$ (33,000)	$ 1,688	$ 31,312	$ 0	$ 0
Issuance of common stock upon warrant exercise (in shares)													0		5,091,351			5,091,000
Issuance of common stock upon warrant exercise													$ 0	0	$ 916,443	9,279,198	0	$ 10,195,641
Balance (in shares) at Jun. 30, 2021													587		125,925,096
Balance at Jun. 30, 2021													$ 1	$ 586,999	$ 22,666,505	$ 240,023,345	$ (119,204,948)	$ 144,071,902